Mary Tagliaferri, M.D.

Mary Tagliaferri, M.D., serves as the Chief Medical Officer at Nektar Therapeutics, where she leverages her extensive experience in pharmaceutical drug development, particularly in oncology and women’s health. With over two decades in the field, Dr. Tagliaferri holds significant regulatory expertise and provides strategic guidance on clinical strategy, medical affairs, and oversees key clinical investigator relationships, as well as medical writing and publication functions at Nektar. She played a pivotal role in the strategic development of Nektar’s immunooncology portfolio, notably bempegaldesleukin, and leads the company’s clinical collaboration with Bristol-Myers Squibb. Prior to her current role, she was a clinical and regulatory consultant to InterMune before its acquisition by Roche and served as Chief Medical Officer at KangLaiTe USA. Dr. Tagliaferri is also a co-founder and was the President and Chief Medical Officer of BioNovo, where she led the company’s global clinical drug development strategy and regulatory affairs. Her contributions to the field have been recognized with the 2012 State of California Woman of the Year award, highlighting her advancements in clinical research in women’s health and her mentorship of women in biotechnology. Dr. Tagliaferri earned her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco (UCSF).